Retatrutide Dosage: What the Trials Actually Used (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice or a dosing guide. Retatrutide is an investigational drug with no FDA-approved dose. The doses below are from published clinical trials only — they are not a protocol to follow. Never self-administer an investigational drug. Consult your doctor.

So you searched "retatrutide dosage" and want a number. Here's the honest answer first: there isn't an approved one. As of June 2026, retatrutide is still an experimental drug, and no health authority has signed off on a dose.

What we can do is document what the actual trials used. Below are the real dose arms, the real titration schedules, and the real weight-loss results from the published studies. Think of this as a record of what was studied — not a plan to copy.

Retatrutide (LY3437943) is a once-weekly injectable. It is the first triple agonist to reach late-stage trials, hitting the GLP-1, GIP, and glucagon receptors at the same time. That third target, glucagon, is what sets it apart from semaglutide and tirzepatide (Eli Lilly, 2026).

Is there an FDA-approved retatrutide dose?

No. There is no FDA-approved dose of retatrutide because the drug itself is not FDA-approved. It remains investigational, available only inside clinical trials.

Eli Lilly is still running Phase 3 studies. The FDA has not reviewed whether retatrutide is safe and effective, which is the legal step every prescription drug must clear before it reaches pharmacies (Eli Lilly, 2026).

That is the content vacuum. Many sites publish "dosage charts" as if a standard exists. It doesn't. Industry analysts at Clarivate project a possible launch around 2028, and even that is a guess (CBS News, 2026).

Until a dose is approved, every number you see comes from a research protocol. Those protocols were run by physicians, under monitoring, with safety oversight. They were not designed for anyone to follow at home.

There's a second wrinkle worth naming. Some clinics and online sellers are offering "retatrutide" anyway, ahead of any approval. The FDA has not vetted those products for safety, strength, or even whether they contain what the label claims (CBS News, 2026).

So when this article lists doses, read them as historical facts about trials. Not as a green light. The gap between "what a trial used" and "what is safe for you to take" is wide, and only a clinician can bridge it.

What doses did the Phase 2 obesity trial use?

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) tested four target doses — 1 mg, 4 mg, 8 mg, and 12 mg once weekly — over 48 weeks in 338 adults. Higher doses produced more weight loss.

This was a randomized, double-blind, placebo-controlled, dose-ranging study. Adults had obesity, or overweight with a weight-related condition, and did not have type 2 diabetes (Jastreboff et al., NEJM 2023).

The results scaled with dose. The table below shows the published mean weight change at 48 weeks (NEJMoa2301972, 2023).

Target dose (weekly)	Starting dose	Weeks studied	Mean weight change at 48 wk
Placebo	—	48	−2.1%
1 mg	1 mg	48	−8.7%
4 mg	2 mg or 4 mg	48	−17.1%
8 mg	2 mg or 4 mg	48	−22.8%
12 mg	2 mg	48	−24.2%

The 12-mg group lost about a quarter of their body weight on average. That figure drew enormous attention. It also drove the search traffic you're part of right now.

Two things to keep in mind. These are group averages, not guarantees. And every participant was monitored closely by a research team (ClinicalTrials.gov, NCT04881760).

One detail often gets lost. The 4-mg and 8-mg arms each split into two sub-groups that used different starting doses — some began at 2 mg, others at 4 mg. The trial did this to study how the on-ramp itself affected tolerability, not just the final dose (NEJMoa2301972, 2023).

That's a research design choice, not a recommendation. It tells you the scientists were still learning how to introduce the drug — which is exactly why a settled "starting dose" doesn't exist yet.

How did the trials titrate (escalate) the dose?

The trials never started anyone at a high dose. Participants began low — 2 mg or 4 mg weekly — and stepped up every 4 weeks until they reached their assigned target. This slow ramp is the whole point of the protocol.

Retatrutide hits three receptors at once: GLP-1, GIP, and glucagon. Each affects the gut, appetite, and energy use. Introducing the drug gradually gives the body time to adapt and keeps nausea and vomiting more manageable (Jastreboff et al., NEJM 2023).

In Phase 2, the design was deliberately complex. Some higher-dose groups started at 2 mg and others at 4 mg, so investigators could compare how the starting point affected side effects. Each dose level was held for about 4 weeks before the next increase (NEJMoa2301972, 2023).

So a participant assigned to 8 mg did not take 8 mg in week one. They climbed there over roughly 12 to 13 weeks. The escalation, not the final number, is what made the dose tolerable.

This is exactly why a "dosage chart" is misleading without context. The schedule was a research tool, calibrated to the support a trial provides.

It's also why the speed of escalation matters as much as the dose. The Phase 2 data suggested that climbing too fast was tied to more gastrointestinal side effects. The 4-week hold at each level wasn't arbitrary — it gave the gut time to settle before the next step (Jastreboff et al., NEJM 2023).

Think of it less like a dose and more like a glide path. The destination is the target dose. How you get there shapes whether you can tolerate the trip at all.

What doses are being tested in TRIUMPH Phase 3?

The pivotal TRIUMPH-1 obesity trial tests three target doses — 4 mg, 9 mg, and 12 mg weekly — and every participant starts at 2 mg. Note the schedule shifted from Phase 2: there is now a 9-mg step, no 8-mg arm.

TRIUMPH-1 (NCT05929066) is an 80-week, randomized, double-blind, placebo-controlled study. It randomized 2,339 adults in equal groups to 4 mg, 9 mg, 12 mg, or placebo (ClinicalTrials.gov, NCT05929066).

The escalation is stepwise, every 4 weeks. Lilly described the path like this (Eli Lilly, 2026):

TRIUMPH-1 target dose	Escalation steps (every 4 wk)
4 mg	2 mg → 4 mg
9 mg	2 mg → 4 mg → 6 mg → 9 mg
12 mg	2 mg → 4 mg → 6 mg → 9 mg → 12 mg

At 80 weeks, the 12-mg group lost an average of about 28.3% of body weight, roughly 70 pounds (Eli Lilly, 2026).

The broader TRIUMPH program studies a fuller set of doses — 2, 4, 6, 9, and 12 mg — across obesity, sleep apnea, and osteoarthritis indications. A separate cardiovascular and kidney outcomes study, TRIUMPH-Outcomes, runs under NCT06383390 (ClinicalTrials.gov, NCT06383390).

Notice what changed between phases. Phase 2 had an 8-mg arm and used two different starting doses. Phase 3 dropped the 8-mg step, added a 9-mg target, and standardized everyone to a single 2-mg start (Eli Lilly, 2026).

That shift matters for anyone reading old "dosage charts." A schedule built from the Phase 2 design is already out of date. The pivotal trials use a different ramp — more evidence that there's no single fixed protocol to copy.

How do trial doses compare to tirzepatide and semaglutide dosing?

Retatrutide's milligram numbers fall in a similar range to tirzepatide but mean nothing on their own — milligrams don't compare across different drugs. Each molecule binds its receptors with different strength.

Here is how the approved drugs are dosed, alongside retatrutide's trial doses. Only the first two rows are FDA-approved (FDA Zepbound label, 2026; Wikipedia: Semaglutide).

Drug	Status	Maintenance dose(s)	Titration
Tirzepatide (Zepbound)	FDA-approved	5, 10, 15 mg weekly	Start 2.5 mg, step every 4 wk
Semaglutide (Wegovy)	FDA-approved	2.4 mg weekly	0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg
Retatrutide	Investigational	None approved	Trial-only: start 2 mg, step every 4 wk

Notice the trap. Retatrutide's 12 mg and Zepbound's 15 mg look close, so people assume they're interchangeable. They are not. A milligram of one drug is not a milligram of another (FDA Zepbound label, 2026).

Semaglutide makes the point even clearer. Its full weight-loss dose is just 2.4 mg — a fraction of retatrutide's numbers — yet it is a powerful drug. Potency, not the number on the syringe, is what matters.

Why you should not use trial doses to self-dose

The doses in this article are research data, not instructions. Using them to self-dose an investigational drug is dangerous and is not what they were designed for. Several reasons stand out.

First, retatrutide sold outside a trial is unregulated. The FDA has not confirmed it is safe or effective, and there is no approved product to buy (CBS News, 2026). Compounded or gray-market versions carry no guarantee of purity, strength, or even identity.

Second, trial participants had a safety net. Doctors screened them, monitored labs, watched for side effects, and adjusted or stopped treatment. The titration schedule only worked inside that structure.

Third, the side-effect profile is real. Nausea, vomiting, and diarrhea were common, and they tracked with dose and speed of escalation. A heart-rate increase was also seen. These need medical oversight (Jastreboff et al., NEJM 2023).

Fourth, the injectable form, the concentration, and the device all matter. Trial participants used study-supplied product at known strengths. A self-dosed milligram from an unverified vial is not the same milligram the NEJM table describes — you can't be sure what you're actually injecting (CBS News, 2026).

If you're interested in this class of drugs, the right move is a conversation with a licensed clinician about approved options. See our complete retatrutide evidence review and our overview of approved GLP-1 medications for context.

What the evidence does not yet establish about optimal dosing

Even after large trials, the "best" retatrutide dose is unsettled. The data show more drug means more weight loss, but they do not yet define an ideal long-term maintenance dose. Several questions remain open.

The dose-response curve had not clearly flattened in Phase 2 — meaning higher doses might still add benefit, but also more side effects. Where the sweet spot sits for an individual is unknown (Jastreboff et al., NEJM 2023).

Long-term safety at each dose is still being collected. The TRIUMPH-Outcomes study is specifically measuring cardiovascular and kidney effects over time (ClinicalTrials.gov, NCT06383390).

We also don't know the final label. If retatrutide is approved, the FDA-cleared maintenance doses and titration steps may differ from any single trial arm. That detail won't exist until approval (Eli Lilly, 2026).

Until then, treat every retatrutide dose as a research finding. Interesting, well-documented, and not a prescription.

Frequently Asked Questions

Is there a standard retatrutide dose in 2026?

No. Retatrutide is investigational with no FDA-approved dose. The only doses that exist are those used in clinical trials, which were run under medical supervision and are not meant to be copied at home.

What was the highest dose used in the obesity trials?

12 mg once weekly was the highest dose in both the Phase 2 NEJM study and the Phase 3 TRIUMPH-1 trial. In TRIUMPH-1, participants reached it by stepping up from 2 mg over several months.

Why did the trials start so low and increase slowly?

Retatrutide activates three receptors that affect the gut and appetite. A slow ramp — usually every 4 weeks — gives the body time to adjust and reduces nausea, vomiting, and diarrhea. The gradual schedule is central to how the drug was tolerated.

How does retatrutide's dose compare to Zepbound or Wegovy?

You can't compare milligrams across these drugs. Each binds its receptors differently. Wegovy's full dose is only 2.4 mg and Zepbound's tops out at 15 mg, yet both are potent. The number on the syringe does not measure strength.

Can I get a retatrutide dosing prescription now?

There is no FDA-approved retatrutide product, so there is no standard prescription. Any retatrutide sold outside a clinical trial is unregulated and unverified. Talk to a licensed clinician about approved alternatives.

Related Reading

• Retatrutide: complete evidence review
• Retatrutide side effects by system and dose
• Next-gen GLP-1 pipeline 2026

-- The GLP-1 Daily Team